| Stereochemistry | ACHIRAL |
| Molecular Formula | C19H23ClN2S |
| Molecular Weight | 346.917 |
| Optical Activity | NONE |
| Defined Stereocenters | 0 / 0 |
| E/Z Centers | 0 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
CCN(CC)CCCN1C2=C(SC3=C1C=C(Cl)C=C3)C=CC=C2
InChI
InChIKey=DBOUGBAQLIXZLV-UHFFFAOYSA-N
InChI=1S/C19H23ClN2S/c1-3-21(4-2)12-7-13-22-16-8-5-6-9-18(16)23-19-11-10-15(20)14-17(19)22/h5-6,8-11,14H,3-4,7,12-13H2,1-2H3
| Molecular Formula | C19H23ClN2S |
| Molecular Weight | 346.917 |
| Charge | 0 |
| Count |
MOL RATIO
1 MOL RATIO (average) |
| Stereochemistry | ACHIRAL |
| Additional Stereochemistry | No |
| Defined Stereocenters | 0 / 0 |
| E/Z Centers | 0 |
| Optical Activity | NONE |
Chlorproethazine (Neuriplege) is a neuroleptic, antipsychotic and muscle relaxant. Neuriplege® cream was available as a non‐prescription medication in France until its withdrawal from the market by regulatory authorities in January 2007. Neuriplege caused phototoxicity and photocontact allergy.
Originator
Approval Year
PubMed
Patents
|
|
SALT/SOLVATE -> PARENT |
Showing 1 to 1 of 1 entries
